Analytical Data
-
Gene name
CCL26
- Application
-
Alternative Names
CCL26；SCYA26；C-C motif chemokine 26
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9Y258
-
Expression Region
24-94aa
-
AA Sequence
TRGSDISKTC CFQYSHKPLP WTWVRSYEFT SNSCSQRAVI FTTKRGKKVC THPRKKWVQK YISLLKTPKQ L
-
Molecular Weight
8.4 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CCL26, also known as eotaxin-3, is a chemokine primarily involved in the recruitment of eosinophils and other immune cells to sites of inflammation, playing a critical role in allergic responses and asthma pathogenesis. It is produced by various cell types, including epithelial cells, and has been implicated in several chronic inflammatory diseases. Research indicates that elevated levels of CCL26 are associated with conditions such as asthma, rhinitis, and atopic dermatitis, highlighting its potential as a biomarker for these diseases. The study of CCL26 has garnered significant interest due to its role in mediating the Th2-type immune response and its involvement in tissue remodeling and fibrosis. Understanding the mechanisms of CCL26 action and signaling pathways could unveil new therapeutic targets for the treatment of allergic diseases and other related disorders. Given the importance of eosinophil infiltration in chronic inflammation, recombinant CCL26 protein studies aim to elucidate its functions in vivo and in vitro, providing insights into potential interventions. Furthermore, the potential use of CCL26 in developing novel therapeutic strategies or targeted treatments could advance the current paradigm of managing allergic diseases, underscoring the need for continued research in this area.
